Table 4.
Gene therapy-based clinical trials for oral cancers
| Product name | Sponsor | Nationality | Estimated date of completion | Phase | Status | Identifier |
|---|---|---|---|---|---|---|
| IL-12 gene medicine | Dana-Farber Cancer Institute | United States | November 2000 | I/II | Completed | NCT00004070 |
| Allovectin-7® | Vical | United States | June 2002 | III | Completed | NCT00050388 |
| E6 TCR gene therapy | National Cancer Institute (NCI) | United States | June 2016 | I/II | Completed | NCT02280811 |
| TheraT® expressing HPV-specific antigens | Hookipa Biotech GmbH | United States | June 2022 | I/II | Recruiting | NCT04180215 |
| HPV-Specific T Cells | Baylor College of Medicine | United States | October 2022 | I | Active, not recruiting | NCT02379520 |
IL-12 interleukin-12; Allovectin-7® HLA-B7/β-2 microglobulin plasmid DNA/lipid complex; E6 TCR E6 T cell receptor; HPV Human papilloma virus